Journal of Pharmacy And Bioallied Sciences
Journal of Pharmacy And Bioallied Sciences Login  | Users Online: 1605  Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size 
    Home | About us | Editorial board | Search | Ahead of print | Current Issue | Past Issues | Instructions | Online submission


REVIEW ARTICLE
Year : 2021  |  Volume : 13  |  Issue : 6  |  Page : 921-926

COVID-2019–2020–2021: Systematic review and meta-analysis


1 Department of Oral and Maxillofacial Surgery, C.K.S. Teja Institute of Dental Sciences, Tirupathi, Andhra Pradesh, India
2 MBBS, Duty Doctor (DMO), Apollo Hospital, Visakhapatnam, Andhra Pradesh, India
3 Kiran's Poly Clinic, Visakhapatnam, Andhra Pradesh, India
4 Department of Prosthodontics, Educare Institute of Dental Sciences, Malappuram, Kerala, India
5 Consultant Oral and Maxillofacial Surgeon, Amritsar, Punjab, India
6 Consultant Dental Surgeon, 3609 Gracie Ct, Cakersfield, CA, USA
7 MPH Student, Parul University, Vadodara, Gujrat, India

Correspondence Address:
Heena Tiwari
Parul University, Limda, Waghodia, Vadodara, Gujrat
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jpbs.jpbs_371_21

Rights and Permissions

Introduction: The world has faced the pandemic of COVID-19 in March 2020 and still it continues to affect in 2021. There is a great variation about the course of the disease and its features. Hence, in the present systemic review, we intend to determine the pooled estimations in the clinical features and prognosis along with the subgroups based on the severity of the disease in various regions of the world. Materials and Methods: Online data were collected from the search engines of EBSCO, PubMed, Google Scholar, and Scopus. The searched terms were COVID 19, CORONA, SARS-CoV-2, clinical features, Wuhan, etc. The study articles were collected that from January 2020 to February 2021. Based on the PRISMA guidelines, a meta-analysis was performed. Results: A total of 5067 articles were selected, of which 176 were finalized for the study. There were a total of 11 countries that were included, with a total of 2½ lakh participants. Mean age was 47.5 years. Around 22.5% had comorbidities. The mortality was 5.5%. We observed a strong association between the medical condition of the patient and the severity of the infection. In severe cases, the most common symptoms were respiratory and gastrointestinal. The mortality was registered in those with pneumonia and end-organ failure. Conclusion: It can be concluded from this meta-analysis that in a fourth of the positive patients, the disease was severe. In nearly 6% of the COVID-19 patients, mortality was seen. Patients with comorbidities and the severe form of the disease should be closely monitored.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

suppl
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed316    
    Printed4    
    Emailed0    
    PDF Downloaded67    
    Comments [Add]    

Recommend this journal